FLGT Fulgent Genetics, Inc.
Price Chart
Executive Summary
Fulgent Genetics announced interim Phase 2 data for FID-007 + cetuximab in R/M HNSCC, showing a 60% objective response rate and 7.2-month median progression-free survival, significantly exceeding historical benchmarks (5.8-19.1% ORR, 2.3-3.7 months PFS). The abstract was accepted for a Rapid Oral Session at ASCO 2026 (June 1). This is a meaningful clinical catalyst that de-risks the pipeline and supports further development.
Actionable Insight
The strong interim efficacy data positions FID-007 as a potential best-in-class therapy for R/M HNSCC. Traders should watch the ASCO 2026 presentation on June 1 for updated data, and monitor for partnership interest or regulatory path announcements. The data could drive significant upside for the stock in the near term.
Key Facts
- Objective response rate (ORR) of 60% in 42 evaluable patients (58% in Arm A, 61% in Arm B)
- Median progression-free survival (mPFS) of 7.2 months (6.7 months Arm A, 7.2 months Arm B)
- Median duration of response (DoR) 7.4 months with 56% of responders continuing to respond at data cutoff
- Historical standard of care ORR 5.8%-19.1% and mPFS 2.3-3.7 months
- Favorable safety profile with mostly Grade 1-2 TRAEs; one Grade 5 pneumonia in Arm B
- Abstract #6020 selected for Rapid Oral Session at ASCO 2026 on June 1, 2026
Financial Impact
No financial projections provided; positive clinical data could support future regulatory filing and partnership / licensing value for FID-007 in a large addressable market (~73,000 US HNSCC cases/year)
Risk Factors
- Interim Phase 2 data – results may not persist in larger Phase 3 trials
- One Grade 5 TRAE (pneumonia) raises safety vigilance
- Competition from approved PD-1 inhibitors and other novel therapies
- Company is a small cap with limited cash runway dependence on pipeline progress
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001674930-26-000025 |
| Document: flgt-ex99_1.htm | 0001674930-26-000025 |
| Document: 0001674930-26-000025-index-headers.html | 0001674930-26-000025 |
| Document: 0001674930-26-000025-index.html | 0001674930-26-000025 |
| Document: 0001674930-26-000025.txt | 0001674930-26-000025 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
12d ago
|
Insider Cluster
| $18.14 $18.14 | · 0.00% | ▲ +0.29% | $18.31 (+0.94%) |
|
May 28, 2026
12d ago
|
Insider Cluster
| $18.14 $19.15 | ▲ +5.57% | ▲ +8.09% | $18.31 (+0.94%) |
|
May 21, 2026
19d ago
|
8-K
| $17.11 $18.09 | ▲ +5.73% | ▲ +4.07% | $18.31 (+7.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access